Biosimilars | Current Treatment | Nephrology | US/EU | 2016

The uptake of biosimilar erythropoiesis-stimulating agents (ESAs) varies from country to country, as well as by drug and manufacturer. European nephrologists have been able to prescribe ESAs to their chronic kidney disease (CKD) patients for a number of years, but no biosimilar ESAs are yet available to U.S. nephrologists. As new biosimilars near the market, including epoetin alpha biosimilars in the United States, it is important to understand how and why ESA biosimilar uptake is so varied. We surveyed French, German, and U.S. nephrologists about their familiarity with, use of, and attitude toward current biosimilars; the drivers and barriers to biosimilars’ uptake; and these physicians’ expectations for novel biosimilars.

launch Related Market Assessment Reports